Pharvaris NV

PHVS · NASDAQ

$31.41+$0.73 (+2.38%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $30.68

PHVS analyst rating

BuyConsensus of 13 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy13
Hold0
Underperform0
Sell0

12-month price target · 16 analysts

Average $59.67 (+90.0% upside)

Low: $42.42
Now: $31.41
High: $82.95

Upgrades and downgrades

The latest rating actions, newest first

PHVS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B of A Securities	Oct 23, 2026	Upgrade	Neutral → Buy	$44.00	46%
Guggenheim	Sep 10, 2026	Maintains	Buy	$40.00 → $44.00	46%
Morgan Stanley	Sep 9, 2026	Maintains	Overweight	$46.00 → $62.00	36%
Leerink Partners	Sep 9, 2026	Maintains	Outperform	$50.00 → $65.00	34%
Wells Fargo	Sep 9, 2026	Maintains	Overweight	$55.00 → $65.00	33%
RBC Capital	Sep 9, 2026	Maintains	Outperform	$52.00 → $62.00	0%
Citizens	Sep 9, 2026	Maintains	Market Outperform	$75.00 → $79.00	46%
Wedbush	Sep 9, 2026	Maintains	Outperform	$42.00 → $50.00	42%
HC Wainwright & Co.	Sep 8, 2026	Maintains	Buy	$60.00	33%
Wedbush	Sep 8, 2026	Maintains	Outperform	$42.00	42%

The case for and against

Updated Oct 21, 2026

Bull case

Pharvaris is viewed favorably because deucrictibant has delivered strong Phase 3 proof of concept in HAE prophylaxis, with an 83% monthly attack-rate reduction overall and 87% in Type 1/2 patients, alongside a clean safety profile that appears competitive with leading injectable options. The company also has meaningful commercial optionality across both prevention and on-demand treatment, supported by positive prior Phase 2 data, a growing open-label extension base, and a differentiated once-daily oral profile that could drive switching from current therapies. Financially, the outlook is strengthened by $363M in cash at 2Q26, which supports runway into 2028, while the cited market opportunity includes roughly €720M WW peak sales for XR and about $300M WW peak sales for IR.

Bear case

Pharvaris is exposed to concentrated pipeline risk because its strategy is heavily dependent on deucrictibant and the bradykinin B2 receptor mechanism, with limited therapeutic diversification and sparse detail on expansion beyond HAE. Although CHAPTER-3 showed an 83% reduction in mean monthly attack rate versus placebo over 24 weeks in 85 patients, the company still faces meaningful clinical uncertainty for prophylaxis, possible chronic safety issues, and a crowded HAE market where differentiation may be difficult. Financially, it remains a non-revenue-generating biotech that will continue to incur net losses and likely need additional capital, creating dilution risk alongside the uncertainty of regulatory approval and commercial uptake.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.